Abemaciclib combined with endocrine therapy improves OS in high-risk HR+, HER2− early breast cancer
Abemaciclib combined with endocrine therapy improves OS in high-risk HR+, HER2− early breast cancer
Durvalumab combined with FLOT improves survival in resectable gastric and GEJ adenocarcinoma
MCED blood test demonstrates high specificity, strong predictive value, and increased early cancer detection
Enhancing breast cancer care through AI and collaboration
NSCLC brain metastases: TTFields after SRS delays intracranial progression without affecting QoL
Apalutamide and salvage radiotherapy benefits luminal B subtype prostate cancer
ctDNA testing improves detection of treatable metastases compared to standard care in colorectal cancer
Non-clear cell renal cell carcinoma: Management of papillary RCC
ADT with PORT is a good treatment option for men with unfavourable intermediate risk or favourable high risk PC
Bladder cancer updates from the first half of 2025
Improving efficacy and toxicity reporting - and treatment insights from an oncologist patient
CURB phase II trial: Tumour burden predicts survival after SBRT in NSCLC oligoprogression